{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:10:09Z","timestamp":1756336209554,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jpainsymman.2024.08.031","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:38:05Z","timestamp":1724877485000},"page":"e491-e499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Dosing Regimen During Rotation From Subcutaneous to Transdermal Administration of Fentanyl"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2911","authenticated-orcid":false,"given":"Bram C.","family":"Agema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Vrielink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-3852","authenticated-orcid":false,"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2468-8878","authenticated-orcid":false,"given":"Frank","family":"van Tienen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.T.","family":"Geijteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-1242","authenticated-orcid":false,"given":"Carin C.D.","family":"Van der Rijt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-7530","authenticated-orcid":false,"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-0501","authenticated-orcid":false,"given":"Astrid W.","family":"Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bcp.13129","article-title":"A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients","volume":"83","author":"Kuip","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0002","first-page":"661","article-title":"The use of opioids in cancer patients with renal impairment-a systematic review","volume":"25","author":"Sande","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0003","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/082585970902500304","article-title":"Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials","volume":"25","author":"Tassinari","year":"2009","journal-title":"J Palliat Care"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0004","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0269216310383739","article-title":"Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project","volume":"25","author":"Radbruch","year":"2011","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00228-015-2005-x","article-title":"Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients","volume":"72","author":"Oosten","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0006","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H","article-title":"A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl","volume":"92","author":"Kornick","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0007","first-page":"691","article-title":"Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study","volume":"19","author":"Nomura","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0008","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"NONMEM tutorial part I: description of commands and options, with simple examples of population analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114823","article-title":"Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients","volume":"163","author":"Lanser","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/j.1875-9114.1989.tb04096.x","article-title":"Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation","volume":"9","author":"Plezia","year":"1989","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0012","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1345\/aph.1D395","article-title":"Continuous subcutaneous infusion of opiates at end-of-life","volume":"38","author":"Anderson","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.09.036","article-title":"Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients","volume":"105","author":"Bechakra","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0885-3924(99)00051-2","article-title":"A comparison of subcutaneous morphine and fentanyl in hospice cancer patients","volume":"18","author":"Hunt","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0885-3924(98)00095-5","article-title":"Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study","volume":"16","author":"Watanabe","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0304-3959(95)00084-6","article-title":"Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management","volume":"63","author":"Paix","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamainternmed.2018.1044","article-title":"Association of an opioid standard of practice intervention with intravenous opioid exposure in hospitalized patients","volume":"178","author":"Ackerman","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0018","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0885-3924(01)00365-7","article-title":"Continuous subcutaneous infusion practices of United States hospices","volume":"22","author":"Herndon","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0019","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cpt.2027","article-title":"Tolerance to opioid-induced respiratory depression in chronic high-dose opioid users: a model-based comparison with opioid-naive individuals","volume":"109","author":"Algera","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clinthera.2008.03.001","article-title":"Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study","volume":"30","author":"Christrup","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0021","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.ftd.0000160717.50704.42","article-title":"Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients","volume":"27","author":"Solassol","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104914","article-title":"Skin penetration and decontamination efficacy following human skin exposure to fentanyl","volume":"67","author":"Thors","year":"2020","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.jpainsymman.2024.08.031_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/pgs-2017-0022","article-title":"Is there a role for pharmacogenetics in the dosing of fentanyl?","volume":"18","author":"Koolen","year":"2017","journal-title":"Pharmacogenomics"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392424009898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392424009898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:52:19Z","timestamp":1756335139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392424009898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0885392424009898"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2024.08.031","relation":{},"ISSN":["0885-3924"],"issn-type":[{"type":"print","value":"0885-3924"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the Dosing Regimen During Rotation From Subcutaneous to Transdermal Administration of Fentanyl","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2024.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.","name":"copyright","label":"Copyright"}]}}